| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC |
| Uniprot No | O00585 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-134aa |
| 氨基酸序列 | SDGGAQDCCLKYSQRKIPAKVVRSYRKQEPSLGCSIPAILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQGCRKDRGASKTGKKGKGSKGCKRTERSQTPKGP |
| 预测分子量 | 43.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SLC重组蛋白的虚构参考文献示例(内容为假设性描述，仅供格式参考)：
1. **《Functional Characterization of Recombinant SLC6A4 Transporter in Mammalian Cells》**
- 作者：Smith A, et al.
- 摘要：研究通过重组表达人源SLC6A4(血清素转运体)于HEK293细胞，分析其转运活性及抗抑郁药物(如SSRIs)的抑制效应，揭示其动力学特性与药物结合位点。
2. **《Structural Insights into SLC2A1 Glucose Transporter via Cryo-EM》**
- 作者：Chen L, et al.
- 摘要：利用冷冻电镜技术解析重组表达的SLC2A1(GLUT1)三维结构，阐明其底物识别机制，为糖尿病相关转运异常提供分子基础。
3. **《Recombinant SLC12A2 in Disease Modeling: Role in Hypertension Pathogenesis》**
- 作者：Wang X, et al.
- 摘要：通过重组SLC12A2(NKCC1)蛋白功能实验，验证其在细胞离子稳态中的作用，并发现特定突变体与高血压发病的关联性。
4. **《High-Yield Expression and Purification of SLC19A1 for Drug Interaction Studies》**
- 作者：Johnson R, et al.
- 摘要：优化SLC19A1(叶酸转运体)的重组表达与纯化流程，评估其与化疗药物(如甲氨蝶呤)的相互作用，为靶向递送策略提供依据。
注：上述文献为模拟内容，实际引用需检索PubMed、Web of Science等数据库获取真实研究。
SLC (Solute Carrier) recombinant proteins are engineered versions of membrane transport proteins belonging to the SLC superfamily, which comprises over 400 members organized into 66 families. These proteins facilitate the transport of diverse substrates, including ions, nutrients, metabolites, and drugs, across cellular membranes. Their roles in maintaining homeostasis, metabolic regulation, and drug pharmacokinetics make them critical targets for understanding diseases like cancer, diabetes, and neurological disorders.
Recombinant SLC proteins are produced using heterologous expression systems (e.g., bacteria, insect, or mammalian cells) to enable detailed structural and functional studies. Advanced gene cloning and protein purification techniques allow researchers to obtain high-purity, active SLC proteins for in vitro assays, crystallography, or cryo-EM analyses. This recombinant approach overcomes challenges in isolating native SLC proteins, which are often low-abundance or unstable.
Therapeutic and diagnostic applications drive interest in SLC recombinant proteins. For example, SLC6A4 (serotonin transporter) is studied in depression, while SLC2A1 (GLUT1) is linked to metabolic diseases. Structural insights from recombinant proteins aid in drug design, particularly for inhibitors or modulators targeting SLC-mediated transport. However, complexities like post-translational modifications, oligomerization, and substrate promiscuity necessitate careful experimental design.
Recent advances in structural biology and computational modeling have accelerated SLC research, revealing transport mechanisms and substrate-binding sites. Recombinant SLC proteins also support high-throughput screening for drug discovery. Despite progress, functional annotation and physiological validation remain ongoing challenges, highlighting the need for integrated molecular and cellular studies.
×
